Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Mayo Clinic
Study ID
NCT06401642
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zavegepant — DRUG
    10 mg intranasal

Study Details

Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.

Key Dates

Start date
Mar 22, 2024
Status verified
Sep 2025
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
200 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Zavegepant Treatment
    Participants will receive zavegepant to treat up to 8 migraine attacks over 24 weeks.

Primary Outcome Measure

Headache relief in 2 hours [ Time Frame: 2 hours ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in ArizonaPhoenixArizona85254
Michael R Leonard
[email protected]
480-342-2908
Dani SMith
[email protected]
480-342-6524
Todd J Schwedt, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Phoenix, AZ

By condition
Migraine
By specialty
Neurology
By research site
Mayo Clinic in Arizona· Phoenix, AZ

Related Studies